No annual revenue total was found in WEREWOLF THERAPEUTICS, INC.'s SEC filings.
Werewolf Therapeutics, Inc. (HOWL) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$60.3 million. As of Jun 30, 2026 it held $22.0 million in cash and investments and $2.5 million in total debt.
Revenue
—
Net income (TTM)
$-34.61M
+52.7% vs year-ago TTM
Operating cash flow (TTM)
$-30.15M
+50.4% vs year-ago TTM
Free cash flow
$-60.29M
-6.8% vs prior year
EPS (TTM)
$-0.71
+56.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
48.60M
+8.4% vs prior year
Net cash
$19.49M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HOWL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1785530
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$60.7M | -$73.6M | -$40.5M | -$56.1M | -$50.1M |
| Net income | -$60.8M | -$70.5M | -$37.4M | -$53.8M | -$50.0M |
| Diluted EPS | -$1.33 | -$1.63 | -$1.05 | -$1.86 | -$10.94 |
| Operating cash flow | -$60.3M | -$56.2M | -$32.6M | -$40.6M | -$42.9M |
| Free cash flow | -$60.3M | -$56.4M | -$33.4M | -$44.2M | -$43.4M |
| Total assets | $69.4M | $126.9M | $174.8M | $160.2M | $179.2M |
| Total liabilities | $44.6M | $53.5M | $63.5M | $37.9M | $26.5M |
| Stockholders' equity | $24.8M | $73.4M | $111.4M | $122.3M | $152.8M |
| Cash and investments | $57.0M | $111.0M | $134.3M | $129.3M | $157.5M |
| Total debt | $41.5M | $43.1M | $52.6M | $14.7M | $15.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 21, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 20, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 450 Werewolf Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.